Literature DB >> 16386987

Longitudinal cohort study of patients with birdshot chorioretinopathy. I. Baseline clinical characteristics.

Dominique Monnet1, Antoine P Brézin, Gary N Holland, Fei Yu, Alfred Mahr, Lynn K Gordon, Ralph D Levinson.   

Abstract

PURPOSE: To describe baseline clinical characteristics of a cohort of 80 patients with birdshot chorioretinopathy in anticipation of a longitudinal study, and to identify relationships between visual acuity, symptoms, and ophthalmic findings.
DESIGN: Single-center cross-sectional study.
METHODS: A standardized examination was performed in the same order on a single day for each patient. A grading system for birdshot lesions was established prospectively to evaluate the following lesion characteristics: quantity, distribution, morphology, and pigmentation. Relationships between clinical features of disease were sought in multivariate analyses that adjusted for age, duration of uveitis, and treatment.
RESULTS: Mean age at baseline examination was 55.6 years. Median best-corrected visual acuity (BCVA) was 0.8 (range, counting fingers to 1.2). There were no relationships between BCVA and any birdshot lesion characteristic. The most common cause of BCVA < or =0.4 was macular edema. Visual symptoms were present in 78 patients (97.5%), including 17 (94.4%) of 18 patients with BCVA > or =1.0 in both eyes. Blurred vision was associated with decreased BCVA (P = .02) and macular edema (P = .022). Increased lesion pigmentation was associated with complaints of blurred vision (P = .030), vibrating vision (P = .011), and nyctalopia (P = .056).
CONCLUSIONS: Symptoms are common in patients with birdshot chorioretinopathy, even among those with good BCVA. Lesion pigmentation may be a marker of decreased visual function that is not reflected in central visual acuity. These findings highlight the limitation of using visual acuity measurements for monitoring patients with birdshot chorioretinopathy and as an outcome measure for studies of this disease.

Entities:  

Mesh:

Year:  2006        PMID: 16386987     DOI: 10.1016/j.ajo.2005.08.067

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  9 in total

Review 1.  Current approach in the diagnosis and management of posterior uveitis.

Authors:  S Sudharshan; Sudha K Ganesh; Jyotirmay Biswas
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

Review 2.  New concepts in the appraisal and management of birdshot retinochoroiditis, a global perspective.

Authors:  Marina Papadia; Carl P Herbort
Journal:  Int Ophthalmol       Date:  2015-02-14       Impact factor: 2.031

3.  Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis).

Authors:  Ilknur Tugal-Tutkun; Carl P Herbort; Moncef Khairallah
Journal:  Int Ophthalmol       Date:  2008-09-16       Impact factor: 2.031

4.  Reappraisal of birdshot retinochoroiditis (BRC): a global approach.

Authors:  Marina Papadia; Carl P Herbort
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-11-18       Impact factor: 3.117

5.  CHOROIDAL LESIONS UNRESPONSIVE TO FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN BIRDSHOT CHORIORETINOPATHY.

Authors:  Shuk Kei Cheng; Ian Thompson; Chinwenwa Okeagu; H Nida Sen
Journal:  Retin Cases Brief Rep       Date:  2022-01-01

6.  Classification Criteria for Birdshot Chorioretinitis.

Authors: 
Journal:  Am J Ophthalmol       Date:  2021-04-15       Impact factor: 5.488

Review 7.  Gender differences in birdshot chorioretinopathy and the white dot syndromes: do they exist?

Authors:  Lisa J Faia
Journal:  J Ophthalmol       Date:  2014-02-09       Impact factor: 1.909

Review 8.  Birdshot Chorioretinopathy: A Review.

Authors:  Elodie Bousquet; Pierre Duraffour; Louis Debillon; Swathi Somisetty; Dominique Monnet; Antoine P Brézin
Journal:  J Clin Med       Date:  2022-08-16       Impact factor: 4.964

Review 9.  Birdshot uveitis: current and emerging treatment options.

Authors:  Victor Menezo; Simon Rj Taylor
Journal:  Clin Ophthalmol       Date:  2013-12-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.